Anaerobic Coverage of Levofloxacin

Clinical Guideline Recommendations

• The Centers for Disease Control and Prevention (CDC) recommends levofloxacin with or without metronidazole for the treatment of pelvic inflammatory disease (PID) 1, 2, 3
• The CDC guidelines state that the lack of anaerobic coverage with ofloxacin is a concern, and the addition of metronidazole to the treatment regimen provides this coverage 2, 3
• The Infectious Diseases Society of America (IDSA) recommends combining levofloxacin with clindamycin for the treatment of moderate-to-severe diabetic foot infections requiring anaerobic coverage 4, 5

Comparison to Other Fluoroquinolones

• Moxifloxacin demonstrates significantly superior anaerobic activity compared to levofloxacin, with approximately 90% susceptibility against Bacteroides species and other anaerobes 6

Clinical Implications

• The CDC recommends adding metronidazole or clindamycin to levofloxacin when treating intra-abdominal infections, pelvic inflammatory disease, and diabetic foot infections (moderate-to-severe) 1, 2, 3, 4, 5
• The IDSA recommends using alternative agents like moxifloxacin, ertapenem, or ampicillin-sulbactam when broad anaerobic coverage is needed 4, 5